// App-Quantinova.ai

104 : PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).

Researchers

Presenter

  • Jonathan E. Rosenberg

Principal Investigators

  • Michiel Simon Van Der Heijden

  • Andrea Necchi

  • Peter H. O'Donnell

  • Yohann Loriot

  • Margitta Retz

  • Jose Luis Perez-Gracia

  • Joaquim Bellmunt

  • Petros Grivas

  • Richard Wayne Joseph

  • Lawrence Fong

  • Edward E. Kadel

  • Zachary Boyd

  • Dorothee Nickles

  • Garrett Michael Frampton

  • Richard Bourgon

  • Priti S. Hegde

  • Sanjeev Mariathasan

  • Thomas Powles

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Yale University, New Haven, CT

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • University of Chicago Comprehensive Cancer Center, Chicago, IL

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Mayo Clinic, Jacksonville, FL

  • University of California, San Francisco, San Francisco, CA

  • Genentech, Inc., South San Francisico, CA

  • Foundation Medicine, Inc, Cambridge, MA

  • Barts Cancer Institute, Barts Health, and The Royal Free London NHS Foundation Trust, London, United Kingdom

Locations

  • Italy

  • Netherlands

  • Germany

  • Spain

  • United Kingdom

  • United States

  • France

Companies

  • Genentech, Inc.

  • Foundation Medicine,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02108652

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved